NDA 019618 · Mylan Speciality Lp
Rowasa
Mesalamine · Rectal · Aminosalicylate
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Oct 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1987
Dec 24, 1987
Approved uses
1
Original approval plus efficacy supplements
Registered trials
188
77 Phase 3, 14 recruiting
FAERS reports
28,157
24,946 serious, 1,988 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 3, 2026.
ROWASA is indicated for the treatment of active mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis in adults. ROWASA is an aminosalicylate indicated for treatment of active mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis in adults. ( 1 )
Mechanism: The mechanism of action of 5-ASA (mesalamine) is not fully understood, but appears to be a topical anti-inflammatory effect on colonic epithelial cells. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways (i.e., prostanoids), and through the lipoxygenase pathways (i.e., leukotrienes and hydroxyeicosatetraenoic acids) is increased in patients with ulcerative colitis, and it is possible that mesalamine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 24, 1987 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
- ROWASA · MESALAMINE 4GM/60ML · ENEMA, RECTAL · Prescription · TE AB
- SFROWASA · MESALAMINE 4GM/60ML · ENEMA, RECTAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Mesalamine" as an intervention, any sponsor and status, largest first.
- CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) RemissionPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT00092508 · 1,725 participants (planned) · Start May 2004
Drug: OPC-6535; Asacol® · For: Ulcerative Colitis
Sites: Huntsville, Alabama; Los Angeles, California; Hollywood, Florida · 26 sites in all
- A Comparison of Once a Day Dose Compared to 2 Doses/DayPivotal-lookingCompleted
Warner ChilcottIndustry
NCT00505778 · 1,027 participants · Start Jul 2007 · Primary completion Jul 2009
Drug: Mesalamine Once-Daily; Mesalamine Twice-Daily · For: Ulcerative Colitis
Sites: Athens, Alabama; Birmingham, Alabama; Dothan, Alabama · 245 sites in all
- Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative ColitisPivotal-lookingCompleted
ShireTakeda (TAK)
NCT00151892 · 829 participants · Start Apr 8, 2005 · Primary completion Sep 7, 2009
Drug: SPD476; Asacol · For: Ulcerative Colitis
Sites: Birmingham, Alabama; Bristol, Connecticut; Washington D.C., District of Columbia · 142 sites in all
- TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)Pivotal-lookingCompleted
Tillotts Pharma AGIndustry
NCT01903252 · 817 participants · Start Jul 2013 · Primary completion May 2016
Drug: TP05; Asacol 400 mg · For: Acute Ulcerative Colitis
Sites: Rheinfelden, Switzerland
- A Double Blind Study for the Treatment of Acute Ulcerative ColitisPivotal-lookingCompleted
Warner ChilcottIndustry
NCT00350415 · 772 participants · Start Jun 2006 · Primary completion May 2007
Drug: Mesalamine · For: Ulcerative Colitis
Sites: Alabaster, Alabama; Birmingham, Alabama; Tucson, Arizona · 135 sites in all
ShireTakeda (TAK)
NCT01124149 · 759 participants · Start Jun 29, 2010 · Primary completion Dec 7, 2012
Drug: MMX mesalamine/ mesalazine · For: Ulcerative Colitis
Sites: Birmingham, Alabama; Anaheim, California; Garden Grove, California · 105 sites in all
- Determination of the Optimal Treatment Target in Ulcerative ColitisPivotal-lookingCompleted
Alimentiv Inc.Academic, hospital or other
NCT04259138 · 672 participants · Start Feb 18, 2020 · Primary completion Apr 13, 2026
Drug: Treatment Algorithm A; Treatment Algorithm B and 1 more · For: Colitis, Ulcerative
Sites: Ypsilanti, Michigan; New York, New York; Asheville, North Carolina · 58 sites in all
- Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)Pivotal-lookingCompleted
Dr. Falk Pharma GmbHIndustry
NCT00746447 · 648 participants · Start May 2005 · Primary completion Apr 2007
Drug: mesalamine granules; mesalamine granules and 1 more · For: Colitis, Ulcerative; Recurrence
Sites: Cologne, Germany
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use6,489
- colitis ulcerative4,631
- drug ineffective4,453
- condition aggravated3,401
- diarrhoea2,667
- haematochezia2,486
- fatigue2,255
- abdominal pain2,185
- weight decreased1,956
- headache1,910
- nausea1,884
- pyrexia1,834
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 126 |
| 2005 | 167 |
| 2006 | 120 |
| 2007 | 167 |
| 2008 | 581 |
| 2009 | 136 |
| 2010 | 281 |
| 2011 | 713 |
| 2012 | 628 |
| 2013 | 180 |
| 2014 | 226 |
| 2015 | 284 |
| 2016 | 338 |
| 2017 | 372 |
| 2018 | 596 |
| 2019 | 736 |
| 2020 | 1,165 |
| 2021 | 2,427 |
| 2022 | 4,173 |
| 2023 | 4,308 |
| 2024 | 4,045 |
| 2025 | 3,998 |
| 2026 | 2,389 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Rowasa (Mesalamine W/Cleansing Wipes)
2024 spending
$44K
Beneficiaries
n/a
17 claims
Per beneficiary
n/a
$370.00 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $335,019 |
| 2021 | $92,430 |
| 2022 | $75,415 |
| 2023 | $69,155 |
| 2024 | $44,029 |
Part D: Sfrowasa (Mesalamine)
2024 spending
$32K
Beneficiaries
12
17 claims
Per beneficiary
$2,665
$0.89 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $53,872 |
| 2021 | $73,510 |
| 2022 | $78,421 |
| 2023 | $29,711 |
| 2024 | $31,979 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.
Kucharzik T, Koletzko S, Kannengiesser K, et al. · Dtsch Arztebl Int 2020 · Meta-Analysis, Review
- Curcumin-QingDai Combination for Patients With Active Ulcerative Colitis: A Randomized, Double-Blinded, Placebo-Controlled Trial.
Ben-Horin S, Salomon N, Karampekos G, et al. · Clin Gastroenterol Hepatol 2024 · Randomized Controlled Trial
- Budesonide for induction of remission in Crohn's disease.
Rezaie A, Kuenzig ME, Benchimol EI, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy of 5-aminosalicylic acid continuation versus discontinuation in patients with ulcerative colitis escalated to advanced therapy: a systematic review and meta-analysis of adjusted effect estimates.
Sul HH, Gewehr DM, Kang H, et al. · J Crohns Colitis 2025 · Systematic Review, Meta-Analysis
- Interventions for treating collagenous colitis.
Kafil TS, Nguyen TM, Patton PH, et al. · Cochrane Database Syst Rev 2017 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Systematic Review and Meta-analysis: Efficacy of Mesalamine in Irritable Bowel Syndrome.
Goodoory VC, Tuteja AK, Black CJ, et al. · Clin Gastroenterol Hepatol 2024 · Meta-Analysis, Systematic Review
Sponsor: Mylan Speciality Lp · Also marketed as Sfrowasa
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.